Researchers of a Swedish study advise physicians to consult with their patients about these risks and take extra precautions, ...
An in-depth analysis of ER+ breast cancer, focusing on its prevalence, molecular biology, current treatments, and emerging ...
PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...
Data derived from Yen T-T, et al. Comparative effects of glucagon-like peptide-1 receptor agonists combined with hormone therapy on endometrial cancer risk among women with benign uterine or ...
“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...
The first patient has been enrolled in the PROSTATE-IQ trial of ArteraAI, a multimodal artificial intelligence biomarker test ...
Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.
Currently, doctors usually check PSA levels about six to eight weeks after surgery. However, a new study from Mass General ...
A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback